Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AbbVie Inc

4AB
Current price
177.18 EUR -0.64 EUR (-0.36%)
Last closed 178.14 EUR
ISIN US00287Y1091
Sector Healthcare
Industry Drug Manufacturers - General
Exchange Frankfurt Exchange
Capitalization 314 612 958 361 EUR
Yield for 12 month +25.36 %
1Y
3Y
5Y
10Y
15Y
4AB
21.11.2021 - 28.11.2021

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

P/E ratio

65.7343

Dividend Yield

3.14 %

Current Year

+49 460 938 758 EUR

Last Year

+52 862 869 374 EUR

Current Quarter

+13 168 822 422 EUR

Last Quarter

+11 209 252 110 EUR

Current Year

+30 871 427 643 EUR

Last Year

+37 006 011 840 EUR

Current Quarter

+9 342 561 060 EUR

Last Quarter

+7 481 333 496 EUR

Key Figures 4AB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 26 117 444 370 EUR
Operating Margin TTM 34.56 %
PE Ratio 65.7343
Return On Assets TTM 7.94 %
PEG Ratio 0.4654
Return On Equity TTM 54.26 %
Wall Street Target Price
Revenue TTM 54 992 509 760 EUR
Book Value 3.84 EUR
Revenue Per Share TTM
Dividend Share 6.13 EUR
Quarterly Revenue Growth YOY 4.3 %
Dividend Yield 3.14 %
Gross Profit TTM 41 521 345 756 EUR
Earnings per share 2.71 EUR
Diluted Eps TTM 2.71 EUR
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY -32.5 %
Profit Margin 9.71 %

Dividend Analytics 4AB

Dividend growth over 5 years

78 %

Continuous growth

7 years

Payout Ratio 5 years average

127 %

Dividend History 4AB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 5.6
Ex Dividend Date 15.10.2024
Forward Annual Dividend Yield 3.14 %
Last Split Factor
Payout Ratio 2.2 %
Last Split Date
Dividend Date

Stock Valuation 4AB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 65.7343
Forward PE 16.3399
Enterprise Value Revenue 7.322
Price Sales TTM 5.721
Enterprise Value EBITDA 22.2651
Price Book MRQ 51.2814

Financials 4AB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 4AB

For 52 weeks

121.74 EUR 181.18 EUR
50 Day MA 174.68 EUR
Shares Short Prior Month
200 Day MA 160.44 EUR
Short Ratio
Shares Short
Short Percent